The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies

The Journal of Pediatrics

Volumn 119, Issue 5, 1991, Pages 679-694

  Pizzo, Phillip A ^a   Rubin, Marc ^a   Freifeld, Alison ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFALOTIN; CEFOPERAZONE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; TRIMETHOPRIM; VANCOMYCIN;

BACTERIAL INFECTION; CHILDHOOD CANCER; FEVER; HUMAN; IMMUNE DEFICIENCY; INFECTION; MYCOSIS; NEUTROPENIA; PARASITOSIS; PREVENTION; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

ANTIBIOTICS; BACTERIAL INFECTIONS; CHILD; FEVER; HUMAN; NEOPLASMS; NEUTROPENIA;

EID: 0025991633     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(05)80281-1     Document Type: Article

References (112)

1. Infections in the cancer patient
2. Infectious complications in the pediatric cancer patient
3. Clinical approach to infections in the compromised host
4. Infectious complications in the child with cancer. I. Pathophysiology of the compromised host and the initial evaluation and management of the febrile cancer patient
5. Alpha-hemolytic streptococci clinical significance in the cancer patient
6. Increasing incidence of gram-positive sepsis in cancer patients
7. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia
8. Septicemia caused by viridans streptococci in neutropenic patients with leukemia
9. Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with Steptococcus viridans
10. Staphylococcus epidermidis septicemia in children with leukemia and lymphoma
11. Empirical and prophylactic antibiotic therapy
12. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever: a statement by the Infectious Disease Society of America
13. Evaluation of fever in the patient with cancer
14. Fever in the pediatric and young adult patient with cancer: a prospective study of 1001 episodes
15. Use of routine chest radiography in the evaluation of fever in neutropenic oncology patients
16. High-resolution ultrafast chest CT in the clinical management of febrile bone marrow transplant patients with normal or nonspecific chest roentgenogra
17. Patterns of oropharyngeal and fecal flora in patients with leukemia
18. Role of serial microbiological surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia
19. Rapid migration of Indium-labeled granulocytes to sites of infection
20. 111In-labeled nonspecific immunoglobulin scanning in the detection of focal infection
21. Antigenemia due to Candida enolase during invasive candidiasis in patients with neoplastic diseases: a prospective multicenter study
22. The polymerase chain reaction: amplifying our options
23. Perspective on the management of catheter-related infections in cancer patients
24. Role of Broviac catheter in infections in children with cancer
25. Atypical mycobacterial infections on Hickman catheter exit sites
26. Primary cutaneous aspergillosis associated with Hickman intravenous catheter
27. Bacillus bacteremia in an immunocompromised patient population: clinical features, therapeutic interventions, and relationship to chronic intravenous catheters in sixteen cases
28. Catheter-associated fungemia in cancer patients: characteristics and clinical outcome
29. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms
30. A prospective study of Hickman/Broviac catheters and implantable ports in pediatric oncology patients
31. Complications of indwelling venous access lines in the pediatric hematology patient a prospective comparison of external venous catheters and subcutaneous parts
32. A randomized trial comparing combination antibiotic therapy to monotherapy in cancer patients with fever and neutropenia
33. Antibiotic therapy in the febrile neutropenic cancer patient clinical efficacy and impact of monotherapy
34. Monotherapy in neutropenic cancer patients
35. After empiric therapy: what to do until the granulocyte count comes back
36. The design, analysis and reporting of clinical trials on the empirical, antibiotic management of the neutropenic patient
37. Imipenemcilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematologic malignancies
38. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia: randomized double-blind, placebo-controlled trial in patients with acute leukemia
39. Vancomycin ticarcillin and amikacin compared with ticarcillin-clavulante and amikacin in the empirical treatment of febrile neutropenic children with cancer
40. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia
41. Vancomycin added to empirical combination therapy for fever in granulocytopenic cancer patients
42. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer
43. Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients
44. Aztreonam therapy in neutropenic patients with cancer
45. Beta-lactam antibiotics
46. Beta-lactam antibiotics
47. The quinolones
48. Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin
49. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin
50. Emerging resistance to fluoroquinolones in staphylococci: an alert
51. Toxicological studies on pipemidic acid vs effect on diarthroidal joints of experimental animals
52. Duration of empiric antibiotic therapy in granulocytopenic cancer patients
53. Approaching the controversies in the antibacterial management of cancer patients
54. Anorectal infections in patients with malignant diseases
55. Treatment of grampositive septicemia in cancer patients
56. Bacteremia caused by nonsporulating anaerobes in cancer patients: a 12-year experience
57. Right lower quadrant complications in young patients with leukemia: a surgical perspective
58. Emergence of Clostridium tertium as a pathogen in neutropenic patients
59. Nosocomial acquisition of Clostridium difficile infection
60. Disease associated with Clostridium difficile infection
61. Candida esophagitis: a prospective study of 27 cases
62. Esophageal infections in immunosuppressed patients after marrow transplant
63. Bacterial esophagitis in immunocompromised patients
64. New pulmonary infiltrates in granulocytopenic patients being treated with antibiotics
65. Induced sputum to diagnose Pneumocystis carinii pneumonia in immunosuppressed pediatric patients
66. A randomized trial of open lung biopsy versus empiric antimicrobial therapy in cancer patients with diffuse pulmonary infiltrates
67. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
68. Empirical amphotericin B in febrile granulocytopenic patients
69. Empiric antifungal therapy in febrile granulocytopenic patients
70. Amphotericin B versus high-dose ketoconazole for empirical antifungal therapy among febrile granulocytopenic cancer patients: a prospective, randomized study
71. Experimental basis for usage of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts
72. Invasive aspergillosis developing during antifungal therapy
73. Considerations for the prevention of infectious complications in patients with cancer
74. Infection management during anti leukemia treatment-induced granulocytopenia the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract
75. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin
76. Prevention of mycoses in immunocompromised patients
77. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia
78. Oral acyclovir for prevention of herpes simplex reactivation after marrow transplant
79. Varicella vaccine (Varivax) in healthy children and adolescents: results from clinical trials, 1987 to 1989
80. Live attenuated varicella vaccine
81. The risk of zoster in leukemia in children who received live attenuated varicella vaccine
82. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation
83. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
84. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
85. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis
86. Safety and pharmacokinetics of 566C80, a hydroxyraphthoquinone with anti-Pneumocystis carinii activity
87. Immunization strategies for the immunocompromised host: the need for immunoadjuvants
88. Efficiacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps and rubella vaccine
89. Antibody production following immunization with diphtheria and tetanus toxoids in children receiving chemotherapy during remission of malignant disease
90. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli
91. Treatment of gram-negative septic shock with human IgG antibody to Escherishia coli J5: a prospective, double-blind, randomized trial
92. Prophylaxis of infectious complications in neutropenic cancer patients with intravenous immunoglobulin
93. Treatment of gramnegative bacteremia and septic shock with HA-IA human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial
94. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia
95. Cost-effectiveness of prophylactic intravenous immunoglobulin in chronic lymphocytic leukemia
96. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome
97. Interleukin-1 and interleukin-1 antagonism
98. A controlled trial of interferon-gamma to prevent infection in chronic granulomatous disease
99. Hematopoietic growth factors: biology and clinical applications
100. Molecular physiology of granulocyte-macrophage colony stimulating factor
101. Effect of recombinant human granulocyte-macrophage colony stimulating factor on chemotherapy-induced myelosuppression
102. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium
103. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for small cell lung cancer
104. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy
105. Acceleration of neutrophilic granulocyte recovery after bone-marrow transplantation by administration of recombinant human granulocyte colony-stimulating factor
106. Effect of recombinant human granulocyte-macrophage colony stimulating factor on hematopoietic recognition after high-dose chemotherapy and autologous bone marrow transplantation
107. Recombinant granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer
108. Effects of recombinant human granulocyte-colony-stimulating factor on hematopoietic progenitor cells in cancer patients
109. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man
110. GM-CSF primed peripheral blood progenitor cells coupled with autologous bone marrow transplantation will eliminate absolute leukopenia following high dose chemotherapy
111. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor
112. Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells